Selpercatinib and capmatinib combination promotes sustained complete response in novel fusion lung cancer after resistance to inhibitor via amplification: Case Report.

fusions occur in 1-2% of non-small cell lung cancer. Selpercatinib and pralsetinib are selective inhibitors with significant improvement of outcome in patients with tumor harboring fusion; however, resistance mechanisms appear frequently, mainly driven by MAPK pathway bypass, secondary mutations, or in 5% via amplification. Co-inhibition of and is a compelling strategy for overcoming -dependent resistance to inhibitors and potentially other inhibitors.

Fibroblastic reticular cell tumour of the internal iliac lymph node presenting as a hypervascular lesion and mimicking a pseudoaneurysm: an extremely rare diagnosis.

A woman in her 50s presented with a rounded and hypervascular lesion in the right internal iliac lymph node chain, contacting with small branches of the anterior division of the internal iliac artery. Since the lesion matched the blood arterial pool in CT and the patient exhibited multiple vascular abnormalities that suggested segmental arterial mediolysis, a pseudoaneurysm hypothesis was initially made. Arteriography was realised due to the intention for embolisation of the pseudoaneurysm, but the dynamic behaviour during the exam suggested a hypervascular tumour more.

Higher frequency of hepatic steatosis at CT among COVID-19-positive patients.

Purpose: Recent studies have demonstrated that obesity is significantly associated with increased disease severity, hospitalizations and mortality in COVID-19, with a potential role in the pathogenesis and prevalence in the new pandemic. The association with hepatic steatosis, however, a condition closely related to obesity within the spectrum of systemic metabolic dysfunctions, remains to be elucidated. We aimed to evaluate the frequency of hepatic steatosis as incidentally detected in chest CT examinations of COVID-19 positive patients in comparison to non-infected controls.